R&D News | pharmaphorum

News

More good news for AbbVie in rheumatoid arthritis

AbbVie has reported positive top-line results for its oral JAK1-selective inhibitor in rheumatoid arthritis (RA), bringing it closer to a potential new early treatment option for patients.

News

Biotech eyes Chinese opportunities and seek local partners

Biotech companies see China as one of the biggest healthcare opportunities, but would need partnerships before approaching the market, a new report suggests.

News

Biogen’s Alzheimer’s drug, elenbecestat, shows early promise

A trial of Biogen’s Alzheimer’s disease drug elenbecestat has had promising results in mild to moderate forms of the disease.

Partner Content

Partner Content

Pharmaceutical Microbiology USA Event takes place in less th...

SMi Pharma Micro West Coast USA

News

AstraZeneca’s respiratory biologic fails again in COPD

AstraZeneca (AZ) and MedImmune, have announced that the latest trial of Fasenra (benralizumab) in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) did not provide a statistically-significant reduction in exacerbations.

News

May champions AI-backed R&D into cancer and chronic disease

Theresa May has pledged to prioritise artificial intelligence (AI) so chronic diseases are diagnosed at an early stage, potentially saving many lives.

More good news for AbbVie in rheumatoid arthritis

Biotech eyes Chinese opportunities and seek local partners

Biogen’s Alzheimer’s drug, elenbecestat, shows early promise

Pharmaceutical Microbiology USA Event takes place in less th...

AstraZeneca’s respiratory biologic fails again in COPD

May champions AI-backed R&D into cancer and chronic disease

Bavarian Nordic has found its new CEO

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks